Breaks Categories: News

FridayJul 25, 2025 3:11 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro Patients

Clene (NASDAQ: CLNN), together with its subsidiary Clene Nanomedicine Inc., is preparing to initiate neurofilament biomarker analyses for its lead drug candidate CNM-Au8(R) in ALS, following feedback from the FDA during a recent Type C meeting. Slated for early Q4 2025, the analyses will assess changes in neurofilament light chain (“NfL”)—a recognized marker for neurodegeneration—among nearly 200 patients treated through the Expanded Access Program for CNM-Au8. “We are encouraged by the FDA’s collaborative approach and their constructive feedback on our NfL biomarker analysis plan from the ongoing NIH-sponsored EAP program,” said Benjamin Greenberg, MD, Head of Medical at Clene. “With…

Continue Reading

WednesdayJul 23, 2025 10:49 am

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL 

Lantern Pharma (NASDAQ: LTRN) announced a complete metabolic response in a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell DLBCL during its ongoing Phase 1 trial of LP-284—the first such response observed with the candidate. The patient had failed three prior regimens, including CAR-T and bispecific antibody therapy, before responding after just two cycles of LP-284, a next-generation acylfulvene developed using Lantern’s RADR(R) AI platform. This outcome highlights LP-284’s synthetic lethal mechanism and potential as a paradigm-shifting therapy for refractory lymphomas, supporting accelerated development and strategic expansion in the $4 billion global B-cell cancer market. To view the…

Continue Reading

TuesdayJul 22, 2025 3:45 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting RedTail Platform and Oncology Advancements

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing targeted genetic medicine therapies, will host an investor webinar on July 24, 2025, at 4:15 p.m. ET. Led by CEO Eric Poma, Ph.D., the event will showcase Calidi’s RedTail(TM) platform, a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. Preclinical data on lead candidate CLD-401 showed tumor elimination and immune memory activation. The company is progressing toward an IND filing and pursuing strategic pharma partnerships to support commercialization. A Q&A session will follow the presentation. To view the full press release, visit https://ibn.fm/hQKmP About Calidi…

Continue Reading

TuesdayJul 22, 2025 11:15 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Virtual Investor Summer Spotlight Conference 

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers of the brain and central nervous system, announced that CEO John Climaco participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. Climaco shared his personal journey, leadership vision and enthusiasm for the company’s development programs. The webcast is available on virtualinvestorco.com and the Events section of the CNS Pharmaceuticals website. To view the full press release, visit https://ibn.fm/SigT8 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the…

Continue Reading

TuesdayJul 22, 2025 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2025 Innovation Award for Remote Cardiac Diagnostics

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, has received the Innovation Award in Remote Cardiac Diagnostics from the 2025 Medical Device Network Excellence Awards. The honor recognizes HeartBeam’s FDA-cleared 3D ECG technology, which enables clinical-grade arrhythmia diagnostics in non-clinical settings via a compact, cable-free device. The synthesized 12-lead ECG software is under FDA review, with commercialization planned upon clearance. This award adds to HeartBeam’s growing list of accolades for its leadership in remote cardiac care. To view the full press release, visit https://ibn.fm/vEL8J About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac…

Continue Reading

MondayJul 21, 2025 9:40 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern’s RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern’s strategic partnership potential. To view…

Continue Reading

FridayJul 18, 2025 3:00 pm

BioMedNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Charts Dual-Path for NRX-100 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. “The company recently filed an application under the newly created FDA Commissioner’s National Priority Voucher (‘CNPV’) program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities,” reads an article discussing NRx. “In parallel, the company has filed an Abbreviated New Drug Application (‘ANDA’) for NRX-100 with a request for priority review. The two pathways, CNPV and ANDA, are expected to complement one another. Should the…

Continue Reading

FridayJul 18, 2025 10:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend

Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board. To view the full report, visit https://ibn.fm/wfve0 About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.…

Continue Reading

FridayJul 18, 2025 9:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508. Each 12 shares of common stock will convert into one, with proportional adjustments to warrants and equity awards. No fractional shares will be issued—holders will receive cash instead. The authorized share count will be reduced to 25 million, while par value remains $0.001. The move is designed to affect all shareholders uniformly. To view the full press release,…

Continue Reading

ThursdayJul 17, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Announces Strategic Partnership and Intent to Acquire BioSpark AI to Advance Drug Repurposing 

Fifty 1 Labs (OTC: FITY) announced a strategic partnership and intent to acquire Vancouver-based BioSpark AI Technologies Inc., a leader in AI and large language model technologies. The alliance merges BioSpark’s literature mining platform with Fifty1’s predictive modeling to extract real-world clinical insights at scale—unlocking overlooked therapeutic patterns for drug repurposing. The partnership will support rapid identification of new formulations focused on performance health and preventative care, with proprietary delivery systems. The move reinforces Fifty1 AI Labs’ vision to lead in AI-powered functional medicine by integrating structured clinical data with advanced Bayesian inference and human-AI collaboration. To view the full…

Continue Reading